CLOSE X

HESTER BIOSCIENCES LTD.

NSE : HESTERBIOBSE : 524669ISIN CODE : INE782E01017Industry : Pharmaceuticals & DrugsHouse : Private
BSE1766.4519.25 (+1.1 %)
PREV CLOSE ( ) 1747.20
OPEN PRICE ( ) 1739.40
BID PRICE (QTY) 1758.35 (2)
OFFER PRICE (QTY) 1766.35 (1)
VOLUME 67
TODAY'S LOW / HIGH ( )1739.40 1767.20
52 WK LOW / HIGH ( )1246.75 3375.45
NSE1766.6017.7 (+1.01 %)
PREV CLOSE( ) 1748.90
OPEN PRICE ( ) 1740.00
BID PRICE (QTY) 1760.70 (2)
OFFER PRICE (QTY) 1765.00 (6)
VOLUME 1521
TODAY'S LOW / HIGH( ) 1730.10 1769.90
52 WK LOW / HIGH ( )1242.95 3379
GO
(Rs.in Million)
Particulars
Mar 2025
Dec 2024
Sep 2024
Jun 2024
Audited / UnAudited
UnAudited
UnAudited
UnAudited
UnAudited
Net Sales
819.25
632.18
836.92
822.67
Total Expenditure
627.44
581.57
645.32
646.17
PBIDT (Excl OI)
191.81
50.61
191.60
176.50
Other Income
-69.50
78.09
18.40
12.25
Operating Profit
122.31
128.70
210.00
188.75
Interest
56.20
-38.12
58.86
50.09
Exceptional Items
NA
NA
NA
NA
PBDT
66.11
166.82
151.14
138.66
Depreciation
41.76
42.91
42.01
41.34
Profit Before Tax
24.35
123.91
109.13
97.32
Tax
22.04
19.58
34.77
31.06
Provisions and contingencies
NA
NA
NA
NA
Profit After Tax
2.31
104.33
74.36
66.26
Extraordinary Items
NA
NA
NA
NA
Prior Period Expenses
NA
NA
NA
NA
Other Adjustments
NA
NA
NA
NA
Net Profit
2.31
104.33
74.36
66.26
Minority Interest
-2.50
2.54
-1.92
-11.50
Shares of Associates
13.1
9.75
9.55
8.6
Other related items
Misc. Expenses Written off
NA
NA
NA
NA
Consolidated Net Profit
12.91
116.62
81.99
63.36
Equity Capital
85.07
85.07
85.07
85.07
Face Value (IN RS)
10.00
10.00
10.00
10.00
Reserves
NA
NA
NA
NA
Calculated EPS
1.52
13.71
9.64
7.45
Calculated EPS (Annualised)
6.07
54.83
38.55
29.79
No of Public Share Holdings
3935921.00
3935921.00
3935921.00
3935921.00
% of Public Share Holdings
46.27
46.27
46.27
46.27
 
NA
NA
NA
NA
PBIDTM% (Excl OI)
23.41
8.01
22.89
21.45
PBIDTM%
14.93
20.36
25.09
22.94
PBDTM%
8.07
26.39
18.06
16.85
PBTM%
2.97
19.60
13.04
11.83
PATM%
0.28
16.50
8.88
8.05
 
Notes
Notes
Notes
Notes
ATTENTION INVESTORS NSDL/CDSL KYC Advisory for investors